SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

LIERN, Miguel; DEREYES, Verónica; FAYAD, Alicia  y  VALLEJO, Graciela. Uso del sirolimus en pacientes con síndrome nefrótico córtico-resistente primario. Nefrología (Madr.) [online]. 2012, vol.32, n.3, pp.321-328. ISSN 0211-6995.

    1. Srivastava T, Somon SD. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 1999;13:13-8. [ Links ]

    2. Alexopoulos E, Stongou M. Factors influencing the course and the response to treatment in primary focal segmental glomeruloesclerosis. Nephrol Dial Transplant 2000;15:1348-56. [ Links ]

    3. Korber SM. Primary focal segmental glomeruloesclerosis. J Am Soc Nephrol 1998;9:1333-40. [ Links ]

    4. Fogo AB. Progression and potential regression of glomeruloesclerosis. Kidney Int 2001;59:804-19. [ Links ]

    5. Cattran DC, Ponduranga R. Long-term outcome in children and adults with classic focal segmental glomeruloesclerosis. Am J Kidney Dis 1998;32:72-9. [ Links ]

    6. Velosa J, Holley K. Significance of proteinuria on the outcome of renal function in patients with focal segmental glomeruloesclerosis. Mayo Clin Proc 1983;58:568-77. [ Links ]

    7. Schweda F, Liebl R. Tacrolimus treatment for steroid and cyclosporine- resistant nephrotic syndrome. Nephrol Dial Transplant 1997;12:2433-5. [ Links ]

    8. Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 2003;18(Suppl 6):79-86. [ Links ]

    9. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, et al. Differential Risk of Remission and ESRD in Childhood FSGS. Pediatr Nephrol 2006;21:344-9. [ Links ]

    10. Zamora, Peña A, Mendizábal S, Bedoya R, Vilalta R, Torra R. Síndrome nefrótico idiopático en el niño. Nefrologia 2007;27(Suppl 2):33-44. [ Links ]

    11. Simón J, Zamora I. Tratamiento del síndrome nefrótico del niño en los inicios del siglo XXI. Nefrologia 2003;23:287-90. [ Links ]

    12. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children (Cochrane Review). En: The Cochrane Library, Issue 2. Oxford: Update Software: 2008. [ Links ]

    13. van Husen M, Kemper M. New therapies in steroid-sensitive and steroid- resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26:881-92. [ Links ]

    14. Cattran DC, Alexopoulos E. Cyclosporine in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney International 2007;72:1429-47. [ Links ]

    15. Aucellia F, Bisceglia L. A genetic viewpoint of focal glomerular sclerosis: from genes to glomerular pathophysiology. G Ital Nefrol 2003;20(4):356-67. [ Links ]

    16. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006;1:109-16. [ Links ]

    17. Lavjay B, Rajendra R. Experience with tacrolimus in children with steroid- resistant nephrotic syndrome. Pediatr Nephrol 2009;24:1517-23. [ Links ]

    18. Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Systematic, review at, 2006. [ Links ]

    19. Serkova N, Christians U. Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Investig Drugs 2003;4:1287-96. [ Links ]

    20. Oppenheimer F, Alonso A, Arias M, Campistol JM, González Molina M, González Posada JM, et al. Manejo de sirolimus en la práctica clínica. Nefrologia 2006;26 Suppl 2:64-93. [ Links ]

    21. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004;19(5):1288-92. [ Links ]

    22. Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE: Comparative Effects of Sirolimus and Mycophenolate Mofetil on Erythropoiesis in Kidney Transplant Patients. Am J Transplant 4 (12): 2001-2006, 2004. [ Links ]

    23. Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer-Bruneel MF, Varet B, et al. Anemia after Late Introduction of Sirolimus May Correlate with Biochemical Evidence of a Chronic Inflammatory State. Transplantation 2005;80(9):1212-9. [ Links ]

    24. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005;79(3):367-8. [ Links ]

    25. Katia S, Annie M, Judith F, Etienne L. Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo blood. Blood 2005;105:103-10. [ Links ]

    26. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002;2(6):551-9. [ Links ]

    27. Flechner SM, Feng J, Mastroianni B, Savas K, Arnovitz J, Moneim H, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005;79(8):926-34. [ Links ]

    28. Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Péraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007;2(2):198-9. [ Links ]

    29. Cho ME, Hurley J, Kopp J, Flechner SM, Feng J, Mastroianni B, Savas K. Sirolimus therapy of focal segmental glomerulosclerosis Is Associated with nephrotoxicity. Am J Kidney Dis 2007;49(2)310-7. [ Links ]

    30. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003;76(2):375-82. [ Links ]

    31. Liern M, Diéguez S, De Reyes V, Vallejos G, Canepa C. Efecto antiproteinúrico del uso aditivo de enalapril y losartan en pacientes pediátricos normotensos con proteinuria. Rev Esp Nefrol 2004;24(6):553-8. [ Links ]

    32. Van Gelder T, Ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75(6):788-91. [ Links ]

    33. Chun M, Korbet J, Schwartz M, Lewis E. Focal Segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15:2169-77. [ Links ]

    34. Barisoni L, Appel G, Seigle R, D'Agati V. Idiopathic collapsing focal segmental glomerulosclerosis: A clinicopathologic study. Kidney Int 1996;50:1734-46. [ Links ]

    35. Bazzi C, Petrini C, Rizza V, Napodano P, Paparella M, Arrigo G, eta al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study. Am J Kidney Dis 2003;41:328-35. [ Links ]

    36. Russo D. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25. [ Links ]